Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study
This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.
Checked against the public recordLast updated Mar 16, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of Southern California
- Interventions being studied
- Other: Non-Interventional Study
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * \* Age ≥ 18 years. * \* Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy) * \* Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint. * \* Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent. Exclusion Criteria: * \* Patients is unable to consent for themselves * \* Patient has not yet completed the 1st cycle of ICI-based therapy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Los Angeles General Medical CenterLos Angeles, California
- USC / Norris Comprehensive Cancer CenterLos Angeles, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 16, 2026. Always confirm current availability with the study team.